Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing its proprietary multiple sclerosis therapy candidate, LUCID-MS, toward a Phase 2 clinical trial following promising Phase 1 results. The therapy is designed to target demyelination and protect or restore myelin integrity, a key pathological feature of multiple sclerosis. Phase 1 studies in healthy volunteers demonstrated a favorable safety profile and general tolerability, supporting the move into patient-focused studies.
In April 2026, the company submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for LUCID-MS, a critical step toward initiating a Phase 2 trial in individuals living with multiple sclerosis. Quantum BioPharma believes LUCID-MS may offer a differentiated, potentially first-in-class approach because it aims to directly address myelin loss and neurodegeneration, rather than relying solely on immune modulation. The company is also strengthening operational support for the program through a planned partnership with Allucent and engagement with neurological specialists.
Multiple sclerosis affects approximately 2.8 million people worldwide, and current treatments primarily focus on modulating the immune system to reduce relapses. However, there is a significant unmet need for therapies that can repair myelin damage and slow disease progression. LUCID-MS is a patented new chemical entity that has shown the ability to prevent and reverse myelin degradation in preclinical models, according to the company.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company focuses on the research and development of LUCID-MS. The company also retains ownership of 19.84% of Unbuzzd Wellness Inc., which markets the OTC product unbuzzd, and is entitled to royalty payments from sales of that product.
The advancement of LUCID-MS into Phase 2 development represents a significant milestone for Quantum BioPharma and the multiple sclerosis community. If successful, the therapy could provide a new treatment option that directly targets the underlying cause of disability in MS. Investors can find the latest news and updates on QNTM in the company’s newsroom at https://ibn.fm/QNTM. The full article discussing this development is available at https://ibn.fm/AUhNl.
